By sequencing of DNA samples, we identified CSF3R mutations in 20.4% (11/54) of patients in the genetically defined CN group, and in 28.5% (2/7) of genetically unclassified CN patients. This evidence concerns the gene CSF3R and cyclic hematopoiesis.